Prelude Therapeutics Analyst Ratings
Prelude Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 68.92% | HC Wainwright & Co. | $6 → $5 | Maintains | Buy |
| 10/19/2023 | 102.7% | HC Wainwright & Co. | $17 → $6 | Maintains | Buy |
| 08/17/2023 | 474.32% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 08/04/2023 | 237.84% | Morgan Stanley | $10 → $10 | Reiterates | Equal-Weight → Equal-Weight |
| 08/04/2023 | 68.92% | Barclays | $7 → $5 | Maintains | Equal-Weight |
| 03/17/2023 | 474.32% | HC Wainwright & Co. | $15 → $17 | Maintains | Buy |
| 11/21/2022 | 102.7% | B of A Securities | → $6 | Downgrades | Neutral → Underperform |
| 11/17/2022 | 406.76% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 11/15/2022 | 237.84% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
| 09/09/2022 | 271.62% | Morgan Stanley | $19 → $11 | Downgrades | Overweight → Equal-Weight |
| 07/29/2022 | 204.05% | Jefferies | → $9 | Initiates Coverage On | → Buy |
| 05/12/2022 | 440.54% | HC Wainwright & Co. | $62 → $16 | Maintains | Buy |
| 03/17/2022 | 541.89% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 03/15/2022 | 237.84% | B of A Securities | $50 → $10 | Downgrades | Buy → Neutral |
| 02/28/2022 | 305.41% | Barclays | $20 → $12 | Downgrades | Overweight → Equal-Weight |
| 11/17/2021 | 575.68% | Barclays | $33 → $20 | Maintains | Overweight |
| 10/11/2021 | 1082.43% | Morgan Stanley | $60 → $35 | Upgrades | Equal-Weight → Overweight |
| 10/08/2021 | 1014.86% | Barclays | $80 → $33 | Maintains | Overweight |
| 07/27/2021 | 1927.03% | B of A Securities | → $60 | Upgrades | Neutral → Buy |
| 04/26/2021 | 1994.59% | HC Wainwright & Co. | → $62 | Initiates Coverage On | → Buy |
| 03/17/2021 | 1927.03% | Morgan Stanley | $47 → $60 | Maintains | Equal-Weight |
| 12/16/2020 | 1487.84% | Morgan Stanley | $38 → $47 | Maintains | Equal-Weight |
| 11/12/2020 | 1183.78% | Morgan Stanley | $34 → $38 | Maintains | Equal-Weight |
| 10/20/2020 | 1251.35% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
| 10/20/2020 | 1150% | Goldman Sachs | → $37 | Initiates Coverage On | → Neutral |
| 10/20/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/07/2023 | 68.92% | HC Wainwright & Co. | 6 美元 → 5 美元 | 維護 | 購買 |
| 2023 年 10 月 19 日 | 102.7% | HC Wainwright & Co. | 17 美元 → 6 美元 | 維護 | 購買 |
| 08/17/2023 | 474.32% | HC Wainwright & Co. | → 17 美元 | 重申 | 購買 → 購買 |
| 08/04/2023 | 237.84% | 摩根士丹利 | 10 美元 → 10 美元 | 重申 | 等重 → 等重 |
| 08/04/2023 | 68.92% | 巴克萊 | 7 美元 → 5 美元 | 維護 | 等重 |
| 03/17/2023 | 474.32% | HC Wainwright & Co. | 15 美元 → 17 美元 | 維護 | 購買 |
| 11/21/2022 | 102.7% | B of A 類證券 | → 6 美元 | 降級 | 中性 → 表現不佳 |
| 11/17/2022 | 406.76% | HC Wainwright & Co. | 16 美元 → 15 美元 | 維護 | 購買 |
| 11/15/2022 | 237.84% | 摩根士丹利 | 11 美元 → 10 美元 | 維護 | 等重 |
| 09/09/2022 | 271.62% | 摩根士丹利 | 19 美元 → 11 美元 | 降級 | 超重 → 重量相等 |
| 07/29/2022 | 204.05% | 傑富瑞集團 | → 9 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/12/2022 | 440.54% | HC Wainwright & Co. | 62 美元 → 16 美元 | 維護 | 購買 |
| 03/17/2022 | 541.89% | 摩根士丹利 | 20 美元 → 19 美元 | 維護 | 超重 |
| 03/15/2022 | 237.84% | B of A 類證券 | 50 美元 → 10 美元 | 降級 | 買入 → 中性 |
| 02/28/2022 | 305.41% | 巴克萊 | 20 美元 → 12 美元 | 降級 | 超重 → 重量相等 |
| 11/17/2021 | 575.68% | 巴克萊 | 33 美元 → 20 美元 | 維護 | 超重 |
| 2021 年 11 月 10 日 | 1082.43% | 摩根士丹利 | 60 美元 → 35 美元 | 升級 | 重量相等 → 超重 |
| 2021 年 8 月 10 日 | 1014.86% | 巴克萊 | 80 美元 → 33 美元 | 維護 | 超重 |
| 2021 年 7 月 27 日 | 1927.03% | B of A 類證券 | → 60 美元 | 升級 | 中性 → 買入 |
| 04/26/2021 | 1994.59% | HC Wainwright & Co. | → 62 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 03/17/2021 | 1927.03% | 摩根士丹利 | 47 美元 → 60 美元 | 維護 | 等重 |
| 2020 年 12 月 16 日 | 1487.84% | 摩根士丹利 | 38 美元 → 47 美元 | 維護 | 等重 |
| 11/12/2020 | 1183.78% | 摩根士丹利 | 34 美元 → 38 美元 | 維護 | 等重 |
| 10/20/2020 | 1251.35% | B of A 類證券 | → 40 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 10/20/2020 | 1150% | 高盛 | → 37 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 10/20/2020 | — | 摩根士丹利 | 啓動覆蓋範圍開啓 | → 重量相等 |
What is the target price for Prelude Therapeutics (PRLD)?
Prelude Therapeutics（PRLD）的目標價格是多少？
The latest price target for Prelude Therapeutics (NASDAQ: PRLD) was reported by HC Wainwright & Co. on November 7, 2023. The analyst firm set a price target for $5.00 expecting PRLD to rise to within 12 months (a possible 68.92% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月7日公佈了Prelude Therapeutics（納斯達克股票代碼：PRLD）的最新目標股價。該分析公司將目標股價設定爲5.00美元，預計PRLD將在12個月內上漲至5美元（可能上漲68.92％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Prelude Therapeutics (PRLD)?
Prelude Therapeutics（PRLD）的最新分析師評級是多少？
The latest analyst rating for Prelude Therapeutics (NASDAQ: PRLD) was provided by HC Wainwright & Co., and Prelude Therapeutics maintained their buy rating.
Prelude Therapeutics（納斯達克股票代碼：PRLD）的最新分析師評級由HC Wainwright & Co. 提供，Prelude Therapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for Prelude Therapeutics (PRLD)?
Prelude Therapeutics（PRLD）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prelude Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prelude Therapeutics was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Prelude Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Prelude Therapeutics的最後一次評級是在2023年11月7日公佈的，因此你應該預計下一個評級將在2024年11月7日左右公佈。
Is the Analyst Rating Prelude Therapeutics (PRLD) correct?
分析師評級 Prelude Therapeutics（PRLD）是否正確？
While ratings are subjective and will change, the latest Prelude Therapeutics (PRLD) rating was a maintained with a price target of $6.00 to $5.00. The current price Prelude Therapeutics (PRLD) is trading at is $2.96, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Prelude Therapeutics（PRLD）評級維持不變，目標股價爲6.00美元至5.00美元。Prelude Therapeutics（PRLD）目前的交易價格爲2.96美元，超出了分析師的預期區間。